Skip to content

Harrow HROW Accounts Receivable Contractual Adjustments

Accounts Receivable Contractual Adjustments at other companies

Henry Schein logo
Henry ScheinHSIC
$2M-57.9%
Ardelyx logo
ArdelyxARDX
$53.43M+116%
CACI International logo
CACI InternationalCACI
$1.51B+22.3%
UnitedHealth Group logo
UnitedHealth GroupUNH
$26.59B-1.3%
Rocket Lab USA, Inc. logo
Rocket Lab USA, Inc.RKLB
$9M+39.5%
Cigna logo
CignaCI
$26.61B-1.2%

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.59B+38.4%
Enterprise value$1.8B+13.8%
P/S5.9×+0.5×

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept HROW:AccountsReceivableContractualAdjustments.

The official record: Harrow’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harrow's accounts receivable contractual adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harrow's accounts receivable contractual adjustments?
Harrow (HROW) reported accounts receivable contractual adjustments of $26.15M in Q4 2025.
What is the long-term trend for Harrow's accounts receivable contractual adjustments?
Over 3 years (2022 to 2025), Harrow's accounts receivable contractual adjustments has grown at a 233.3% compound annual growth rate (CAGR), from $706K to $26.15M.
What does accounts receivable contractual adjustments mean?
This represents the estimated reductions to gross accounts receivable resulting from contractual agreements with payers, such as managed care organizations or government programs. It reflects the difference between the gross invoiced price and the expected net realizable value of receivables. Tracking this helps analysts understand the impact of pricing concessions and payer mix on net revenue realization.